Home / Stocks / Dr Agarwals Health Care L
AGARWALEYE

Dr Agarwals Health Care L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹553.1

Change

+3.6 (0.66%)

Open

₹550.3

Prev. Close

₹549.5

Day High

₹558.5

Day Low

₹544.7

Volume Analysis

Traded

188,847

Delivered

119,973

Delivery %

63.53%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (28.0%)

Weaknesses (1)

  • •Low return on equity (6.41%)

Opportunities (1)

  • •Strong 3-year revenue growth (26.9%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹573.3 ₹565.9 ₹559.5 ₹552.1 ₹545.7 ₹538.3 ₹531.9
Fibonacci ₹565.9 ₹560.63 ₹557.37 ₹552.1 ₹546.83 ₹543.57 ₹538.3
Camarilla ₹556.9 ₹555.63 ₹554.37 ₹552.1 ₹551.84 ₹550.57 ₹549.31

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+10.56%

1 Week

+0.34%

1 Month

+19.07%

3 Months

+10.58%

6 Months

+15.39%

1 Year

+11.76%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹81.68

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

5.91%

Net margin 8.68% × asset turnover 0.41x × equity multiplier 1.66x

Company Overview

Sector

Healthcare

Market Cap

₹17,460 Cr

P/E (TTM)

97.5

ROE

6.41%

Book Value

₹70.6

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Dr Agarwals Health Care L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Growth (100/100), while Valuation (1/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (28.0%); low return on equity (6.41%). FII holding has been falling.

TopFund Score — Fundamentals Quality

66/100 — Good

Data confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

86

Growth

100

Valuation

1

Cash Flow

79

Corporate Governance

44

Momentum

88

Institutional Ownership

66

Business Quality

62

Risk & Volatility

71

Liquidity

44

From Screener.in

  • −Stock is trading at 7.80 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has a low return on equity of 5.94% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Dr Agarwal’s Health Care signed media agreement with GoodEdge Advisory on November 16, 2026.

Transcript of the Discussion held on the Unaudited Financial Results (Consolidated & Standalone) of the Company for the quarter and half year ended September 30, …

Audio recording of the November 5, 2026 earnings call for Q2 and half-year FY2026-27 results posted.

ICRA report for quarter ended September 30, 2026 shows IPO proceeds used as per objects, with no material deviation.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 333 349 403 417 431 460 487 499 530 564 614 655
Expenses + 244 241 300 310 316 329 360 363 386 403 444 480
Operating Profit 89 108 104 107 115 131 128 136 144 161 170 176
OPM % 27.0% 31.0% 26.0% 26.0% 27.0% 28.0% 26.0% 27.0% 27.0% 29.0% 28.0% 27.0%
Other Income + 12 20 6 12 13 13 13 8 11 14 6 10
Interest 22 27 27 28 28 25 25 23 21 22 23 23
Depreciation 43 47 56 57 58 60 63 68 69 77 78 83
Profit before tax 36 54 27 33 41 59 54 54 65 77 75 80
Tax % 37.0% 24.0% 33.0% 36.0% 31.0% 27.0% 29.0% 32.0% 33.0% 35.0% 27.0% 29.0%
Net Profit + 23 41 18 21 28 43 38 36 44 50 55 57
EPS in Rs — — — — 1 1 1 1 1 1 2 2
Raw PDF — — — — — — — — — — — —
YoY Sales growth — — — — 29 32 21 20 23 23 26 31

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 202 531 471 696 1,018 1,332 1,711 2,080 2,363
Expenses + 186 407 387 510 743 965 1,248 1,503 1,712
Operating Profit 16 124 85 186 275 367 463 577 652
OPM % 8.0% 23.0% 18.0% 27.0% 27.0% 28.0% 27.0% 28.0% 28.0%
Other Income + 5 13 6 17 14 44 43 46 41
Interest 20 54 44 49 76 101 115 98 90
Depreciation 21 93 95 98 128 170 231 276 306
Profit before tax -20 -11 -48 57 84 141 160 249 296
Tax % 0.0% 82.0% 21.0% 24.0% -24.0% 32.0% 31.0% 32.0% —
Net Profit + -20 -21 -59 43 103 95 110 168 205
EPS in Rs — — — — — — 3 4 6
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth — — -11 48 46 31 28 22 26

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 290 242 177 206 622 1,330 1,835 1,994 2,206
Borrowings + 135 162 185 633 857 966 961 1,066 1,182
Other Liabilities + 60 339 417 179 336 445 837 849 788
Total Liabilities 492 751 787 1,025 1,823 2,751 3,665 3,941 4,207
Fixed Assets + 99 551 575 701 1,293 1,746 2,523 2,870 3,163
CWIP 1 8 11 28 99 118 153 244 250
Investments 238 1 0 0 34 471 264 152 71
Other Assets + 154 192 201 295 397 416 724 675 724
Total Assets 492 751 787 1,025 1,823 2,751 3,665 3,941 4,207
Equity Capital 7 7 7 7 8 9 32 32 32

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + — 103 99 164 233 346 357 519
Cash from Investing Activity + — -85 -46 -155 -509 -914 -750 -308
Cash from Financing Activity + — -73 -37 35 303 553 382 -220
Net Cash Flow — -56 17 44 27 -15 -11 -10
Free Cash Flow — -98 66 95 76 118 37 59
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit — 97 126 97 98 103 85 99

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 32.45% → 32.33%
  Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 1.74% 1.87% 1.52% 1.78% 1.87% 1.97% 2.23%
Promoters 32.45% 32.43% 32.43% 32.39% 32.35% 32.34% 32.33%
FII 60.62% 59.26% 58.13% 58.06% 57.94% 57.97% 49.56%
DII 5.21% 6.44% 7.92% 7.78% 7.83% 7.72% 15.86%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Dr Agarwals Health Care L (this stock) 17,460 97.5 7.8 6.41%
Cohance Lifesciences Ltd 17,511 359.0 4.49 4.89%
Pfizer Ltd 17,601 115.0 12.74 19.8%
Shilpa Medicare Ltd 17,616 55.1 6.39 9.3%
Alivus Life Sciences Ltd 17,803 50.6 — —
Molbio Diagnostics Ltd 17,111 236.0 11.89 15.6%
Caplin Point Lab Ltd. 17,863 25.9 4.58 20.9%

Which Mutual Funds Hold Dr Agarwals Health Care L?

Frequently Asked Questions about Dr Agarwals Health Care L

Community Sentiment

What are other investors saying about Dr Agarwals Health Care L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.